Press Releases
Explore Roquette’s latest press releases for corporate, sustainability, and business market news.
Filter
Pharma
Published May 09, 2023
PEARLITOL® ProTec Excipient for Stability of Probiotic Supplements
Roquette Spotlights Stability in Probiotic Supplements with Launch of New Excipient PEARLITOL® ProTec Co-Processed Mannitol-Starch at Vitafoods Europe 2023
Pharma
Published April 19, 2023
$25 Million Pharmaceutical Innovation Center in the USA
Roquette celebrates the grand opening of its new Pharmaceutical Innovation Center, located near Philadelphia, Pennsylvania, right in the heart of the United States’ Northeastern pharmaceutical corridor.
Food
Published March 23, 2023
PharmaBiome and Roquette Collaborate on the Development of Tailored Fibers
This partnership aims to design brand new nutrition and health ingredients targeting an optimal interaction with gut microbiota to contribute to a healthy diet.
Food
Published February 23, 2023
AlinOVeg, “Innovating in Plant-Based Food”
Roquette, Agri Obtentions, Eurial, Greencell, INRAE and the Université Lumière Lyon 2, have announced the launch of an ambitious collaborative project: AlinOVeg "Innovating in plant-based food".
Corporate
Published January 23, 2023
Roquette Invests in DAIZ, an Innovative Japanese Food Tech Startup
This partnership is one more step towards Roquette’s vision of tastier and healthier plant-based ingredients that respond to global consumers’ expectations.
Pharma
Published October 31, 2022
Launch of Next-Generation Direct Compression Solutions
CPHI Frankfurt 2022: New PEARLITOL® CR-H mannitol and PEARLITOL® 200 GT mannitol are unveiled. Join the Roquette team on stand 80C90 (Excipient Gold area) to discover the latest innovations in direct compression technology, designed to overcome unique drug formulation challenges and support expansion into novel application areas.
Food
Published October 13, 2022
Roquette Launches Organic Pea Ingredients to Meet Consumer Demand
This new line of organic pea ingredients reinforces its leadership position in the food revolution.
Corporate
Published September 20, 2022
Roquette Finalizes Complete Acquisition of Crest Cellulose
Roquette today announces its complete acquisition of India-based excipient manufacturer, Crest Cellulose.
Pharma
Published July 05, 2022
Roquette expands PEARLITOL® SD mannitol range for APIs
Developed specifically for active pharmaceutical ingredients (APIs) that are highly sensitive to reducing sugars, PEARLITOL® 150 SD supports opportunities to unlock advanced tablet dosage forms – even when using challenging active ingredients.
Food
Published June 23, 2022
Roquette Launches a New Rice Protein
The company extends its NUTRALYS® plant protein range to better address consumer demand for healthier food.
Food
Published June 01, 2022
New NUTRALYS® organic range of texturized pea and fava proteins
This launch enhances Roquette’s strong position on the overall protein market as a key leader for plant-based solutions and supports the company’s effort to be the best partner for customers wishing to develop new and delicious plant-based foods.
Cosmetics
Published April 05, 2022
Launch of a New Microbiome-Friendly Ingredient
Roquette Beauté unveils a new microbiome-friendly ingredient during in-cosmetics® Global in Paris. Beauté by Roquette® DE 006 is a 100% plant-based soothing ingredient for skin and scalp that also preserves the diversity of skin microbiome
Corporate
Published March 22, 2022
€25 million Investment for Polyols at Lestrem site, France
Roquette invests €25 million at its site in Lestrem, France, to strengthen its unique position in the polyols market.
Corporate
Published March 15, 2022
Roquette Canada named one of Manitoba’s Top Employers
Roquetten, which operates the world’s largest pea protein plant in Portage la Prairie, has been named one of Manitoba’s Top Employers for the third year in a row.
Pharma
Published February 28, 2022
Cell therapy acceleration strategy - OPTI-STEM project
The OPTI-STEM project aims to optimize the production of MSCs in order to democratize access to them and thus allow the diversification of therapeutic applications of this type of cells and their derivatives (exosomes, etc.).